Amyloid-related imaging abnormalities

Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
onsdag, maj 15, 2024
Cash, Security (finance), Classification, Patient, SIGNAL, Plasma, Gene expression, Semaphorin, Quarter, Prevalence, Investment, Letter, Neurodegenerative disease, Listing, Bank statement, Health, 8-K, GFAP, Research, Cancer, Neuron, Biomarker, Dementia, Security, ARIA, Brain, Observation, Glial fibrillary acidic protein, Astrocyte, Neurotoxicity, Amyloid-related imaging abnormalities, Pharmaceutical industry

ROCHESTER, N.Y., May 15, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of Semaphorin 4D (SEMA4D), today announced financial results for the first quarter ended March 31, 2024, and provided a corporate update on its key program for Alzheimer’s disease.

Key Points: 
  • Financial Results for the Quarter Ended March 31, 2024:
    Cash and Cash Equivalents and Marketable Securities.
  • Research and development expenses for the quarter ended March 31, 2024, were $3.4 million as compared to $3.8 million for the comparable period in 2023.
  • General and administrative expenses for the quarter ended March 31, 2024, were $1.8 million as compared to $1.7 million for the comparable period in 2023.
  • Stockholders’ Equity as of March 31, 2024, was $2.7 million on March 31, 2024, as compared to a deficit of $(2.3) million on December 31, 2023.

Hyperfine, Inc. Celebrates ASNR 2024

Retrieved on: 
onsdag, maj 22, 2024
Biotechnology, Neurology, Medical Devices, Health, Health Technology, Patient, Diagnosis, FDA, MRI, MD, Workflow, ARIA, Society, Amyloid-related imaging abnormalities, Annual general meeting, Medical imaging

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that the company participated in the American Society of Neuroradiology (ASNR) 2024 Annual Meeting held in Las Vegas between May 18–22, 2024.

Key Points: 
  • Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that the company participated in the American Society of Neuroradiology (ASNR) 2024 Annual Meeting held in Las Vegas between May 18–22, 2024.
  • This event featured several sessions showcasing the unique capabilities of the Swoop® Portable MR Imaging® system.
  • There was significant additional focus on the importance of MRI in the care of Alzheimer’s patients—an area of great opportunity for portable MR imaging.
  • Highlights from the 2024 ASNR Annual Meeting include:
    Ultra-low-field, portable MR brain imaging was featured as a high-potential technology that could have significant diagnostic impact across many disease states.

Hyperfine, Inc. Takes the Stage at ISMRM with Seventeen Abstracts Assessing the Potential of Using Swoop® System Images Across Multiple Care Settings and Clinical Conditions

Retrieved on: 
tisdag, april 23, 2024
Medical Devices, Health, Neurology, Health Technology, Clinical Trials, Radiology, FDA, Brain, International Society, Amyloid-related imaging abnormalities, ARIA, Abstract, Conference, CARE, Patient, Magnetic resonance, Observational study, Physician, Multiple sclerosis, Hyperfine structure, Biomarker, Medical imaging

These seventeen abstracts span a wide variety of use cases, including two that highlight the utility of brain images acquired with the ultra-low-field Swoop® Portable MR Imaging® system to aid physicians screening for various biomarkers and monitoring disease progression unique to neurodegenerative diseases, including Alzheimer’s and multiple sclerosis (MS).

Key Points: 
  • These seventeen abstracts span a wide variety of use cases, including two that highlight the utility of brain images acquired with the ultra-low-field Swoop® Portable MR Imaging® system to aid physicians screening for various biomarkers and monitoring disease progression unique to neurodegenerative diseases, including Alzheimer’s and multiple sclerosis (MS).
  • Conference attendees can learn more during these select presentations:
    “These abstracts are very encouraging.
  • Earlier this month, the company announced that the first patients have been scanned in the CARE PMR (Capturing ARIA Risk Equitably with Portable MR) study.
  • For more information about the Swoop® Portable MR Imaging® system, please visit hyperfine.io.

Leading Institutions Enroll First Alzheimer’s Patients Receiving Amyloid-Targeting Therapy in CARE PMR Study

Retrieved on: 
onsdag, april 17, 2024
Medical Devices, FDA, Health, Health Technology, Clinical Trials, General Health, Brain, Patient, Bleeding, Amyloid-related imaging abnormalities, Mass, ARIA, Workflow, Dementia, CARE, DRS, Radiology, Observational study, Physician, PMR, MRI, Multimedia, Hyperfine structure, Mass General Brigham, Medical imaging

Patients with Alzheimer’s can now be treated with amyloid-targeting therapy, which reduces the amyloid plaque burden in the brain.

Key Points: 
  • Patients with Alzheimer’s can now be treated with amyloid-targeting therapy, which reduces the amyloid plaque burden in the brain.
  • Teresa Gomez-Isla and W. Taylor Kimberly, will evaluate the Swoop® system to understand its potential role in the overall continuum of Alzheimer’s care.
  • “The newly approved amyloid-targeting therapy represents a major milestone in the global fight against Alzheimer’s, bringing hope of additional years of independent living to patients.
  • The required MRI scans to image brain abnormalities in patients receiving amyloid-targeting therapy present workflow challenges for patients and providers,” said Hyperfine, Inc. President and CEO Maria Sainz.

Cognito Therapeutics Announces Spectris™ OVERTURE OLE Study Data Supports Potential Disease Modification and Early Treatment in Alzheimer’s Disease

Retrieved on: 
måndag, mars 11, 2024
Software, Research, Hardware, Pharmaceutical, Data Management, Technology, Medical Devices, Clinical Trials, Science, Neurology, Biotechnology, Health, Other Science, Cognito, Conference, MRI, HOPE, Parkinson's disease, Disease, Patient, Amyloid-related imaging abnormalities, OLE, ARIA, Clinical trial, Therapy, Safety, WBV, Pharmaceutical industry

The results support for Spectris’™ potential as a disease modifying therapy that, if approved, could also be used as an early intervention for the treatment of Alzheimer’s Disease (AD).

Key Points: 
  • The results support for Spectris’™ potential as a disease modifying therapy that, if approved, could also be used as an early intervention for the treatment of Alzheimer’s Disease (AD).
  • These results provide support for the potential safety of prolonged treatment and highlight the potential for Spectris as a potential disease modifying therapy to preserve both brain structure and function in patients with AD,” said Brent Vaughan, CEO of Cognito Therapeutics.
  • 83% of the OVERTURE study patients (44/53) entered a separate 12-month open label extension (OLE) study, which allowed for further evaluation of Spectris’ potential as a disease modifying therapy.
  • “These results are consistent with accepted criteria for disease modification and support potential for use as early treatment of AD.

Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
tisdag, februari 27, 2024
PD, GSK, Arnon Rosenthal, Investment, Interest, ARIA, AbbVie, Webcast, Plasma, PET, MRI, Central nervous system, Traffic barrier, GPNMB, Cerebrospinal fluid, Breakthrough therapy, ALEC, Frontotemporal dementia, FTD, DSM-IV codes, European Medicines Agency, Food and Drug Administration, Canadian International Council, Brain, SAN, Total, LTE, Amyloid-related imaging abnormalities, Alector, ALS, AAIC, PROGRESS, ABC, Manuscript, Conference, Safety, Biomarker, Patent, CSF, Mutation, IND, Microglia, European Patent Convention, Insurance, PIN, FDA, Food, Risk, TREM2, Dementia, Disease, Pharmaceutical industry

Alector and GSK are co-developing AL101 for the potential treatment of more prevalent neurodegenerative diseases, including AD and Parkinson’s disease.

Key Points: 
  • Alector and GSK are co-developing AL101 for the potential treatment of more prevalent neurodegenerative diseases, including AD and Parkinson’s disease.
  • In September 2023, Alector completed enrollment of 381 participants in the randomized, double-blind, placebo-controlled, dose-ranging, INVOKE-2 Phase 2 clinical trial.
  • In July 2023, Alector presented an update on INVOKE-2 at the Alzheimer’s Association International Conference (AAIC).
  • Alector’s management team will host a conference call discussing Alector’s results for the fourth quarter and full year 2023 and provide a business update.

Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Retrieved on: 
tisdag, februari 27, 2024
MPS II, Hearing, ARIA, Antibody, LRRK2, PTV, IDS, Transferrin receptor, MAPT, Traffic barrier, ALS, Hunting, Dermatan sulfate, Therapy, BBB, SAN, Total, Amyloid-related imaging abnormalities, Alpha-synuclein, COMPASS, ETV, Hunter syndrome, Neurodegenerative disease, Conference, MPS, Safety, Biomarker, OTV, LUMA, AFL, SNCA, Amyloid beta, CSF, PIPE, Glycogen storage disease, Research, ATV, FDA, Food, Risk, Sanofi, UC, CD98, Patient, Cognition, Oligonucleotide, Science, Alfa, Pharmaceutical industry

Enrollment continues in the global Phase 2/3 COMPASS study and is expected to be completed in 2024.

Key Points: 
  • Enrollment continues in the global Phase 2/3 COMPASS study and is expected to be completed in 2024.
  • Sanofi intends to present the detailed efficacy and safety results of the ALS Phase 2 HIMALAYA study at a future scientific forum.
  • There was no collaboration revenue for the quarter ended December 31, 2023, compared to $10.3 million for the quarter ended December 31, 2022.
  • Further, for the quarter ended December 31, 2023, there was also a decrease in other unallocated research and development expenses as a result of reduced facility costs.

Cognito Therapeutics OVERTURE Clinical Trial in Alzheimer's Disease Published in Frontiers in Neurology

Retrieved on: 
onsdag, mars 6, 2024
Technology, Medical Devices, General Health, Neurology, Science, Consumer, Clinical Trials, Biotechnology, Health, Health Technology, Other Science, Research, Software, Hardware, Pharmaceutical, Data Management, Seniors, Cognito, Caregiver, Amyloid-related imaging abnormalities, Aes, HOPE, Alzheimer's disease, Political moderate, ARIA, Safety, Hope, Therapy, Memory, EEG, Tolerability, Patient, Clinical trial, Atrophy, MRI, Medical imaging

Cognito Therapeutics , a leader in technology-based therapeutic interventions for neurodegenerative diseases, announced today the publication of the OVERTURE study results in Frontiers in Neurology .

Key Points: 
  • Cognito Therapeutics , a leader in technology-based therapeutic interventions for neurodegenerative diseases, announced today the publication of the OVERTURE study results in Frontiers in Neurology .
  • The OVERTURE clinical trial was a randomized, double-blind, sham-controlled clinical trial conducted over a six-month period at 5 US clinical trial sites, involving participants with mild to moderate AD.
  • Participants were randomly assigned 2:1 to receive self-administered daily, one-hour Spectris therapy designed to evoke EEG-verified gamma oscillations or sham treatment.
  • “Publication of OVERTURE clinical trial results is an important step in our commitment to develop our technology-based therapeutic intervention in Alzheimer’s disease,” said Ralph Kern, M.D., MHSc, Chief Medical Officer of Cognito Therapeutics.

Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

Retrieved on: 
måndag, januari 8, 2024
CSF, Lysosomal storage disease, Cerebrospinal fluid, Risk, Sanfilippo syndrome, Amyloid, BBB, UC, Sanfilippo, Manuscript, ETV, ALS, OTV, SNCA, IDS, Asos, Conference, Cognition, RIPK1, Fluid mechanics, Neuroinflammation, Premedication, Glycogen storage disease, Amyloid beta, SGSH, Therapy, COMPASS, Traffic barrier, Hunting, N-sulfoglucosamine sulfohydrolase, Hunter syndrome, ISR, NewCo, Amyloid-related imaging abnormalities, Inflammation, CNS, Neurodegenerative disease, Takeda, Biomarker, Alpha-synuclein, K2, Biology, DSM-IV codes, LUMA, Brain, MPS, Investigational New Drug, PTV, ARIA, Nerve, AFL, Pathology, MPS II, Interim, BioRxiv, Plaque, MAPT, LRRK2, Elevator mechanic

The global Phase 2/3 COMPASS study continues to recruit up to 54 participants with neuronopathic and non-neuronopathic MPS II.

Key Points: 
  • The global Phase 2/3 COMPASS study continues to recruit up to 54 participants with neuronopathic and non-neuronopathic MPS II.
  • Upon completion of the ongoing Phase 1/2 study, and together with data from COMPASS, this combined data package is intended to support registration.
  • Increased RIPK1 activity in the CNS is hypothesized to drive neuroinflammation and cell necroptosis and to contribute to neurodegeneration.
  • Denali will maintain ownership of and continue to advance its current portfolio of clinical stage small molecule programs.

"LEQEMBI Intravenous Infusion"Lecanemab) for the Treatment of Alzheimer's Disease to be Launched in Japan on December 20

Retrieved on: 
torsdag, december 14, 2023
Marketing, Alzheimer's disease, Caregiver, Government, Radiology, Disease, Pharmacist, Brain, Amyloid-related imaging abnormalities, ARIA, Nursing, Ministry, Patient, Diagnosis, MCI, NHI

The launch in Japan marks the second country to have LEQEMBI on the market, following the U.S.

Key Points: 
  • The launch in Japan marks the second country to have LEQEMBI on the market, following the U.S.
  • In Japan, Eisai and Biogen Japan will co-promote LEQEMBI, with Eisai distributing the product as the Marketing Authorization Holder.
  • In consideration of the importance of Alzheimer's disease in Japan, we believe it is imperative that such pathways be established.
  • We are committed to taking this first step towards changing the future of Alzheimer's disease together with our stakeholders."